Literature DB >> 20671758

Denosumab.

René Rizzoli, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20671758     DOI： 10.1038/nrd3244

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  15 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Discoveries, drugs and skeletal disorders.

Authors:  David Goltzman
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

3.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

4.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Authors:  Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

Review 5.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

6.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Authors:  David L Kendler; Christian Roux; Claude Laurent Benhamou; Jacques P Brown; Michael Lillestol; Suresh Siddhanti; Hoi-Shen Man; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

7.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

9.  Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women.

Authors:  K Lippuner; H Johansson; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-10-31       Impact factor: 4.507

10.  Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Authors:  Paul J Kostenuik; Hung Q Nguyen; James McCabe; Kelly S Warmington; Carol Kurahara; Ning Sun; Ching Chen; Luke Li; Russ C Cattley; Gwyneth Van; Shelia Scully; Robin Elliott; Mario Grisanti; Sean Morony; Hong Lin Tan; Frank Asuncion; Xiaodong Li; Michael S Ominsky; Marina Stolina; Denise Dwyer; William C Dougall; Nessa Hawkins; William J Boyle; William S Simonet; John K Sullivan
Journal:  J Bone Miner Res       Date:  2009-02       Impact factor: 6.741
View more
  18 in total

Review 1.  Stem cell therapy for osteoporosis.

Authors:  Ben Antebi; Gadi Pelled; Dan Gazit
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

2.  Denosumab.

Authors:  Eline A Dubois; Robert Rissmann; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.

Authors:  Yuyu Li; Zhenqi Shi; Joel Jules; Shenyuan Chen; Robert A Kesterson; Dongfeng Zhao; Ping Zhang; Xu Feng
Journal:  J Bone Miner Res       Date:  2019-08-02       Impact factor: 6.741

Review 4.  The pharmacological management of osteoporosis.

Authors:  Amy E Riek; Dwight A Towler
Journal:  Mo Med       Date:  2011 Mar-Apr

Review 5.  Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Authors:  Anil Kapoor; Christopher Wu; Bobby Shayegan; Adrian P Rybak
Journal:  Can Urol Assoc J       Date:  2016-12-12       Impact factor: 1.862

6.  HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia.

Authors:  Jingyu Xiang; Daniel A Rauch; Devra D Huey; Amanda R Panfil; Xiaogang Cheng; Alison K Esser; Xinming Su; John C Harding; Yalin Xu; Gregory C Fox; Francesca Fontana; Takayuki Kobayashi; Junyi Su; Hemalatha Sundaramoorthi; Wing Hing Wong; Yizhen Jia; Thomas J Rosol; Deborah J Veis; Patrick L Green; Stefan Niewiesk; Lee Ratner; Katherine N Weilbaecher
Journal:  JCI Insight       Date:  2019-10-03

Review 7.  Bone-seeking agents for the treatment of bone disorders.

Authors:  Jacqueline Cawthray; Ellen Wasan; Kishor Wasan
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 8.  Treatment of post-menopausal osteoporosis: beyond bisphosphonates.

Authors:  S Ishtiaq; I Fogelman; G Hampson
Journal:  J Endocrinol Invest       Date:  2014-09-07       Impact factor: 4.256

9.  Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.

Authors:  C Thongprayoon; P Acharya; C Acharya; J Chenbhanich; T Bathini; B Boonpheng; K Sharma; K Wijarnpreecha; P Ungprasert; M L Gonzalez Suarez; W Cheungpasitporn
Journal:  Osteoporos Int       Date:  2018-04-30       Impact factor: 4.507

Review 10.  Denosumab: mechanism of action and clinical outcomes.

Authors:  D A Hanley; J D Adachi; A Bell; V Brown
Journal:  Int J Clin Pract       Date:  2012-09-12       Impact factor: 2.503
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.